Treatment of CML (Chronic myeloid leukaemia)
07/25/2016

This press release concerns CML which is a cancer that mainly targets bone marrow and blood. Awareness is necessary for to tackle this deadly disease.

Online PR News – 25-July-2016 – Sydney – Chronic myeloid leukaemia is a cancer that mainly targets bone marrow and blood. It consist an oncogene BCR/ABL that is not present in normal cells. This gene makes a protein BCR/ABL that supports the growth of CML cells. Presence of point mutations in BCR-ABL1 has been implicated as a mechanism for development of imatinib resistance . In order to access the amino acid sequence of the target protein, the protein Abl 1 (Abelson murine leukemia viral oncogene homolog 1) searched in the protein data base on NCBI. Various hits appeared out of which the protein with PDB. On examining the structure of protein, it revealed that there are nine peptide ligand binding sites present in the protein structure while it also carries one large and two small pockets for polypeptide binding. The introduction of TKIs and their implementation in the treatment of CML have changed the management and outcome of this disease dramatically. See complete story at Cancer Health Care Assignment.